Additional file 1: of Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study) Henri Roché Jean-Christophe Eymard Abderraouf Radji Alain Prevost Rafik Diab Michele Lamuraglia Ravaka-Fatoma Soumoudronga Isabelle Gasnereau Alain Toledano 10.6084/m9.figshare.7355576.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Biosimilar_filgrastim_treatment_patterns_and_prevention_of_febrile_neutropenia_a_prospective_multicentre_study_in_France_in_patients_with_solid_tumours_the_ZOH_study_/7355576 Table S1. Reasons for premature withdrawal (n = 294). Table S2. Most common planned CT therapies for patients with ST (analysis population; n = 1174). Table S3. Characteristics of treatment with Zarzio® during the study in patients with follow up (n = 1141). Table S4. Summary of adverse events (n = 62) experienced by ST patients during the study. (DOCX 22 kb) 2018-11-16 05:00:00 Biosimilar pharmaceuticals Filgrastim Febrile neutropenia Real-world Chemotherapy Solid tumours Guidelines recommendations Observational study